Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for serious cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan. Co.'s programs include: TNX-103 and TNX-102 (levosimendan), a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and TNX-201(imatinib), a tyrosine kinase inhibitor, which changed the treatment of chronic myeloid leukemia. We show 21 historical shares outstanding datapoints in our coverage of TENX's shares outstanding history.
Understanding the changing numbers of TENX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TENX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TENX by allowing them to research TENX shares outstanding history
as well as any other stock in our coverage universe. |
Free TENX Email Alerts:
Video: Shares Outstanding Importance
